Overview

Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol; C group : Routine treatment + Probucol; D group: Routine treatment+ Cilostazol+ Probucol .

Phase:

Phase 4

Details

Lead Sponsor:

Otsuka Beijing Research Institute

Treatments:

Cilostazol
Probucol